Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Germany's Askion to manufacture Electro-Optical Sciences (EOS) MelaFind for US clinical trials:

This article was originally published in Clinica

Executive Summary

Electro-Optical Sciences (EOS), an Irvington, New York-based developer of noninvasive, point-of-care devices for early diagnosis of melanoma, has appointed Askion, of Gera, Germany, as manufacturer of its hand-held imaging product MelaFind. The device will undergo clinical trials in the US to establish its safety and efficacy in the imaging of suspicious skin lesions. Data from the trials will be submitted in support of a US premarket approval, which EOS expects to receive in 2007. Financial terms of the agreement were not disclosed. Melanomas are responsible for 80% of all skin cancer deaths. Early diagnosis is essential to ensure good survival rates as there is no cure for advanced stage melanoma.

You may also be interested in...

Agios’ Phase III Data Move It Closer To First Therapy For Rare Anemia

Strong top-line efficacy in pyruvate kinase deficiency patients who don’t receive regular transfusions looks approvable, analysts say, but Agios will await data in regularly transfused patients.

US Payers Rate ICER Assessment Updates Using Real World Data As Potentially ‘High Impact’

ICON survey finds payers increasingly use ICER reports at multiple ‘touchpoints’ during the drug evaluation and decision-making process and the most common use reported in 2020 was as a reference in rebate and pricing negotiations.

Most Pharmacies Ready For COVID-19 Vaccines; Ultra-Cold Storage Still A Limitation

Results of a forthcoming APhA survey showed about one-third cannot store Pfizer/BioNTech's BNT162b2, but can handle Moderna's mRNA-1273.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts